Warning: Last items in stock!
Sofosbuvir and Daclatasvir are hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1 or 3 infection. Limitations of Use: • Sustained virologic response (SVR12) rates are reduced in genotype 3 patients with cirrhosis receiving DAKLINZA in combination with sofosbuvir for 12 weeks.
|Warnings||Don't take the drug without consulting a qualified doctor or physician|
|Suggested use||Follow the doctor's advice|
|Delivery & Returns||7-14 Days|